Vaccine Immune Recovery After Leukemia

Enrolling by invitationOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
OTHER

Observational only: Serology and flow cytometry for ALL cohort participants

Blood samples from ALL cohort participants will be tested to measure antibodies to vaccine-preventable diseases and immune recovery

OTHER

Observational only: Infection rates

Number of infections during the study period will be obtained from both ALL cohort and healthy control participants and captured for comparison and evaluation of infection rates during the first year off-chemotherapy.

Trial Locations (6)

19104

Children's Hospital of Philadelphia, Philadelphia

37232

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville

49503

Helen DeVos Children's Hospital, Grand Rapids

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

78207

CHRISTUS Children's (Affiliate of Baylor College of Medicine), San Antonio

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Children's Hospital of Philadelphia

OTHER